Sophia Genetics SA

NASDAQ SOPH

Data sourced from

and

Download Data

Sophia Genetics SA Shareholders' Equity for the quarter ending March 31, 2024: USD 132.23 M

Sophia Genetics SA Shareholders' Equity is USD 132.23 M for the quarter ending March 31, 2024, a -28.49% change year over year. Shareholders' Equity is the residual interest in the assets of a company after deducting liabilities, representing the shareholders' ownership claim.

Sophia Genetics SA Shareholders' Equity for the quarter ending March 31, 2023 was USD 184.91 M, a -26.60% change year over year.
Sophia Genetics SA Shareholders' Equity for the quarter ending March 31, 2022 was USD 251.91 M, a 206.93% change year over year.
Sophia Genetics SA Shareholders' Equity for the quarter ending March 31, 2021 was USD 82.08 M.

NASDAQ: SOPH

Sophia Genetics SA

CEO	Dr. Jurgi Camblong M.B.A., Ph.D.
IPO Date	July 23, 2021
Location	Switzerland
Headquarters	Rue du Centre 172, Saint-Sulpice, Switzerland, 1025
Employees	430
Sector	Healthcare
Industry	Health information services

Description

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Rolle, Switzerland.

Key trends